(PubMed) Carmichael SL, Yang W, Shaw GM
Tesamorelin modulates the GH/IGF-1 axis to preferentially reduce visceral fat in specific clinical populations
RJVA-001 will be the first candidate from Fractyls Rejuva platform to enter clinical development
A Bayesian hierarchical model was fitted using the brms framework, specifying percent weight change as a Gaussian outcome with (i) drug-specific smooth dose effects (splines by drug), (ii) treatment duration included as a covariate to account for variability in follow-up time across trials, and (iii) a study-level random intercept to account for between-trial heterogeneity
Independent patent analysis, using resources like DrugPatentWatch to verify which patents are actually blocking entry and on what timeline, gives payers the negotiating leverage that comes from knowing the brands position as well as the brand does
Individual Health Goals : The decision to start Semaglutide should also consider the individuals health goals